Health
DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025
DaVita, a steadfast leader in kidney care research and innovation, is unveiling six new studies at the American Society of Nephrology's (ASN) Kidney Week 2025, taking place Nov. 5-9 in Houston, Texas. These studies reflect DaVita's ongoing commitment to advancing kidney treatment through data-driven insights — spanning dialysis treatments, including emerging pathways to middle molecule clearance, and expanding access to transplantation, end-of-life care and more. As DaVita celebrates 25 years of
About this update from Davita Inc.
[{"type":"text","content":"Six new studies from DaVita Clinical Research spotlight improved outcomes with GLP-1 use, advancements in treatments, transplant access and end-of-life care","length":162,"tagName":"p"},{"type":"text","content":"DENVER and HOUSTON, Nov. 4, 2025 /PRNewswire/ -- DaVita, a steadfast leader in kidney care research and innovation, is unveiling six new studies at the American Society of Nephrology's (ASN) Kidney Week 2025, taking place Nov. 5-9 in Houston, Texas. These studies reflect DaVita's ongoing commitment to advancing kidney treatment through data-driven insights — spanning dialysis treatments, including emerging pathways to middle molecule clearance, and expanding access to transplantation, end-of-life care and more. As DaVita celebrates 25 years of clinical innovation, its research continues to push the boundaries of what's possible in improving outcomes and quality of life for patients with kidney disease.","length":723,"tagName":"p"},{"type":"text","content":""Kidney Week isn't just a conference — it's a catalyst," said Steven Brunelli, MD, vice president of research for DaVita. "This year's data challenges conventional thinking and pushes the boundaries of what kidney care can be. From smarter treatments to more equitable transplant access, our research is redefining the patient journey."","length":368,"tagName":"p"},{"type":"text","content":"DaVita will showcase groundbreaking research at the upcoming event, highlighted by an oral presentation from Dr. Steven Brunelli titled "GLP-1 Receptor Agonist Use Associated with Improvement in Hospitalization Rates in Patients with ESKD." This study, which explores how GLP-1 receptor agonists may reduce hospitalizations among patients with end-stage kidney disease, was authored by Rizwan Qazi (Kidney Specialists of Southern Nevada), Terrence Bjordahl (University of Utah, Department of Medicine, Division of Nephrology), and DaVita researchers Steph Karpinski, Scott Sibbel, Eric Weinhandl, Francesca Tentori and Steven Brunelli. The project originated from DaVita's innovative program inviting independent medical directors to submit research ideas, ensuring studies reflect real-world perspectives from prescribing nephrologists.","length":851,"tagName":"p"},{"type":"text","content":"This year, poster presentations from DaVit...